Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Pishvaian on Precision Medicine in GI Cancer

Michael Pishvaian, MD, PhD
Published: Tuesday, Feb 13, 2018



Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses the use of precision medicine, specifically molecular profiling in patients with gastrointestinal (GI) cancers.

The use of expanded testing, or what is more commonly called molecular profiling for patients with different GI cancers is a promising area of investigation. Physicians hope to use predictive biomarkers as an avenue that will direct them toward more individualized therapies.

The term “actionability” is often used to describe a biomarker that predicts full responsiveness, or at least a high responsiveness to a certain therapy. Sometimes that therapy is approved and used in the cancer that is being treated, and sometimes it’s approved and used in a different cancer. Ultimately, that biomarker seems to have promise in the cancer you’re treating.

Research is also investigating optimal methods of identification, specifically the identification of one biomarker versus several, as in broad molecular profiling.
 


Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses the use of precision medicine, specifically molecular profiling in patients with gastrointestinal (GI) cancers.

The use of expanded testing, or what is more commonly called molecular profiling for patients with different GI cancers is a promising area of investigation. Physicians hope to use predictive biomarkers as an avenue that will direct them toward more individualized therapies.

The term “actionability” is often used to describe a biomarker that predicts full responsiveness, or at least a high responsiveness to a certain therapy. Sometimes that therapy is approved and used in the cancer that is being treated, and sometimes it’s approved and used in a different cancer. Ultimately, that biomarker seems to have promise in the cancer you’re treating.

Research is also investigating optimal methods of identification, specifically the identification of one biomarker versus several, as in broad molecular profiling.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x